Emerald Bioscience Stock Revenue
Emerald Bioscience fundamentals help investors to digest information that contributes to Emerald Bioscience's financial success or failures. It also enables traders to predict the movement of Emerald OTC Stock. The fundamental analysis module provides a way to measure Emerald Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emerald Bioscience otc stock.
Emerald |
Emerald Bioscience OTC Stock Revenue Analysis
Emerald Bioscience's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Emerald Bioscience Revenue | 399.91 K |
Most of Emerald Bioscience's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emerald Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Emerald Bioscience reported 399.91 K of revenue. This is 99.99% lower than that of the Healthcare sector and 99.95% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Emerald Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emerald Bioscience's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Emerald Bioscience could also be used in its relative valuation, which is a method of valuing Emerald Bioscience by comparing valuation metrics of similar companies.Emerald Bioscience is currently under evaluation in revenue category among related companies.
Emerald Fundamentals
| Return On Equity | -740.91 | |||
| Return On Asset | -224.1 | |||
| Current Valuation | 86.55 M | |||
| Shares Outstanding | 133.91 M | |||
| Shares Owned By Insiders | 59.50 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (0.62) X | |||
| Price To Book | (9.09) X | |||
| Revenue | 399.91 K | |||
| Gross Profit | 166.22 K | |||
| EBITDA | (4.51 M) | |||
| Net Income | (19.19 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.36 M | |||
| Debt To Equity | (2.11) % | |||
| Current Ratio | 0.12 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (3.94 M) | |||
| Earnings Per Share | (0.16) X | |||
| Beta | -0.04 | |||
| Market Capitalization | 87.04 M | |||
| Total Asset | 692 K | |||
| Retained Earnings | (9.84 M) | |||
| Working Capital | (206 K) | |||
| Current Asset | 635 K | |||
| Current Liabilities | 841 K | |||
| Z Score | -1.0 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Emerald OTC Stock
If you are still planning to invest in Emerald Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emerald Bioscience's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets |